LENZ Therapeutics, Inc.
Ticker: 1815776
values in millions
Revenue & Profit Trend
in millionsRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 |
|---|---|---|---|---|
| INCOME | ||||
| Revenue | 5.49+188.9% | 1.90-84.8% | 12.50+150.0% | 5.00 |
| Total Income | 5.49+188.9% | 1.90-84.8% | 12.50+150.0% | 5.00 |
| EXPENSES | ||||
| Expenditure | 39.66-13.9% | 46.04+46.7% | 31.39+43.6% | 21.86 |
| Tax | 0.00 | — | 0.00-100.0% | 0.50 |
| PROFIT | ||||
| PBT | -31.92 | — | -16.70-15.9% | -14.41 |
| Net Profit | -31.92+23.1% | -41.49-148.4% | -16.70-12.0% | -14.91 |
| KEY METRICS | ||||
| OPM % | -100.00% | -100.00% | -100.00% | -100.00% |
| NPM % | -100.00% | -100.00% | -100.00% | -100.00% |
| EPS | -1.02+22.7% | -1.32-123.7% | -0.59-11.3% | -0.53 |
Corporate Events
Board MeetingLENZ
20261Dec
Board Meeting
Eef Schimmelpennink transitions from President and Chief Exe…
SEC Filing ↗ Board MeetingLENZ
202630Jun
Board Meeting
Zach Scheiner resigned from the Board of Directors and all c…
SEC Filing ↗ Board MeetingLENZ
202612Jun
Board Meeting
Annual Meeting of Stockholders to elect Class II directors a…
SEC Filing ↗